GLP-1受体激动剂与SGLT2抑制剂联合治疗2型糖尿病的临床效果与安全性评估

Clinical Efficacy and Safety Assessment of GLP-1 Receptor Agonist Combined with SGLT2 Inhibitors in Type 2 Diabetes Mellitus

目的探讨胰高糖素样肽-1(glucagon-like peptide-1,GLP-1)受体激动剂与钠-葡萄糖协同转运蛋白2(sodium-dependent glucose transporters 2,SGLT2)抑制剂联合治疗2型糖尿病(type 2 diabetes mellitus,T2DM)的效果。方法选取2022年1月—2024年1月贵州省安顺市人民医院收治的60例T2DM患者为研究对象,按照治疗方法的不同分为两组,各30例。对照组采用二甲双胍、GLP-1受体激动剂治疗,观察组采用GLP-1受体激动剂、SGLT2抑制剂治疗。比较两组血糖指标、血脂指标及不良反应。结果治疗后,观察组空腹血糖、餐后2 h血糖、糖化血红蛋白水平均低于对照组,差异有统计学意义(P均<0.05)。治疗后,观察组总胆固醇、低密度脂蛋白水平均低于对照组,差异有统计学意义(P均<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论GLP-1受体激动剂与SGLT2抑制剂联合治疗T2DM的效果较为理想,可控制患者血糖水平,改善患者血脂指标,且药物安全性较高。

Objective To investigate the effect of glucagon-like peptide-1(GLP-1)receptor agonist combined with sodium-dependent glucose transporters 2(SGLT2)inhibitor in the treatment of type 2 diabetes mellitus(T2DM).Methods A total of 60 patients with T2DM admitted to People's Hospital of Anshun City Guizhou Province from January 2022 to January 2024 were selected as the research objects and divided into two groups according to different treatment methods,with 30 cases in each group.The control group was treated with metformin and GLP-1 receptor agonist,while the observation group was treated with GLP-1 receptor agonist and SGLT2 inhibitor.The blood glucose indexes,blood lipid indexes and adverse reactions were compared between the two groups.Results After treatment,the levels of fasting plasma glucose,2-hour postprandial plasma glucose and glycated hemoglobin A1c in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).After treatment,the levels of total cholesterol and low density lipoprotein in the observation group were lower than those in the control group,and the differences were statistically significant(both P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of GLP-1 receptor agonist and SGLT2 inhibitor is effective in the treatment of T2DM,which can control the blood glucose level of patients,improve the blood lipid index of patients,and has high drug safety.